Publications & Resources

The U.S. Food and Drug Administration has granted Eli Lilly and Company an emergency use authorization for bamlanivimab to treat mild-to-moderate COVID-19 in adult and pediatric patients.

Ventilator-associated pneumonia (VAP) is serious and deadly, but good oral healthcare can substantially reduce the likelihood that individuals connected to a mechanical ventilator contract VAP.

To support policyholders as they navigate the pandemic, MLMIC has assembled a summary of predictive tools and technology to guide management and treatment of COVID-19.

Improved treatment of COVID-19 is reducing mortality rates among those hospitalized for the infection, but experts caution the virus remains dangerous.

The U.S. Food and Drug Administration has approved the antiviral drug remdesivir, sold as Veklury, to treat COVID-19 patients who meet specific criteria.

Based on a series of patient testimonials, the National Institute for Health Research says that ‘long COVID’ could actually be up to four different syndromes.

As use of telehealth continues to grow, physicians are advised to consider key factors when determining whether a virtual visit is the best option for a patient.

As telehealth use continues to rise, physicians are strongly encouraged to adopt practices that can help reduce the risk of an associated medical malpractice claim.

Patient satisfaction is an integral part of providing healthcare, regardless of the clinical setting. All physician office practices should have a policy or protocol in place to address patient complaints. Review this Risk Management Tip from MLMIC to reinforce related policies and protocols within your practice or facility.

A new prediction model, called the COVID Inpatient Risk Calculator, can help forecast if a patient is at high risk of developing severe COVID-19 or dying from the virus.